The IPO Buzz: Parabilis Medicines (PBLS) Prices Upsized IPO at $20 – Above Range & Stock Pops

Let’s do this again: Cancer biotech Parabilis Medicines (PBLS) upsized its IPO at pricing to 33.5 million shares – up from 33.33 million shares – and priced the deal at $20.00 - $1.00 above the top of its range – to raise $670 million on Tuesday night, June 9, 2026. It was the IPO’s second upsizing of the day. Early Tuesday morning, Parabilis Medicines (PBLS) increased its IPO..

Read more June 10, 2026

IPO Calendar

Company Symbol proposed Lead Managers Shares (Millions) Price Low Price High Est. $ Volume Expected to Trade SCOOP Rating Rating Change
ERock, Inc. EROC Morgan Stanley/J.P. Morgan/Barclays/BofA Securities/Evercore ISI/Wolfe Nomura Alliance/BNP Paribas 27.9 21.50 21.50 $ 600.1 mil 6/10/2026 Priced S/O S/O
JAB Acquisition Corp. I JABU D. Boral Capital (ex-EF Hutton) 15.0 10.00 10.00 $ 150.0 mil 6/10/2026 Priced S/O S/O
Parabilis Medicines PBLS Leerink Partners/BofA Securities/Evercore ISI/Guggenheim Partners/LifeSci Capital 33.5 20.00 20.00 $ 670.0 mil 6/10/2026 Priced S/O S/O
Read more

Last 100 IPOs - June 9, 2026

Number of IPOs priced : 100
Number Up: 53
Number Down: 45
Number Unchanged: 2
Percentage Change From Issue Price: 7.68%
Percentage Change for The Nasdaq Composite 35.22%

2026 IPO Scorecard - June 9, 2026

Number of IPOs priced (Excluding 106 units) : 79
Number Up: 42
Number Down: 35
Number Unchanged: 2
Total Return From Issue Price: 6.89%
The Nasdaq Composite Index YTD % Change 35.22%